Expert Interview
Discussing the potential of JAK inhibition in dermatomyositis, with a focus on brepocitinib from Roivant.
Ticker(s): ROIVInstitution: Johns Hopkins
- Assistant Professor of Medicine in the Division of Rheumatology at the Johns Hopkins School of Medicine & Director of Clinical Trials at the Johns Hopkins Myositis Center.
- Actively manages 50+ patients with dermatomyositis.
- Research focus is in overlap myositis in particular studying the spectrum of skeletal myopathy in systemic sclerosis and investigating novel therapeutics in refractory dermatomyositis.
How are dermatomyositis patients treated?
Added By: wilson_adminHow strong is the rationale for JAK1/TYK2 inhibition in dermatomyositis?
Added By: wilson_adminAre you concerned about the AE profile we've seen from systemic dosing of JAK inhibitors?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
